subscribeSubscribe
AbbVie: Atogepant Long-Term Migraine Data At AAN

AbbVie: Atogepant Long-Term Migraine Data At AAN
PR NEWSWIRE
12 Apr 2024
Share Share
AbbVie Announces European Commission Approval of AQUIPTA for Migraine

AbbVie Announces European Commission Approval of AQUIPTA for Migraine
PRESS RELEASE
18 Aug 2023
Share Share
CHMP recommends AbbVie`s migraine drug, GSK`s anemia treatment

CHMP recommends AbbVie`s migraine drug, GSK`s anemia treatment
Paul Schloesser ENDPTS
24 Jun 2023
Share Share
AbbVie reveals results from pivotal atogepant trial

AbbVie reveals results from pivotal atogepant trial
John Pinching PHARMA TIMES
21 Apr 2023
Share Share
AbbVie`s Qulipta gains approval to prevent chronic migraines

AbbVie`s Qulipta gains approval to prevent chronic migraines
Tyler Patchen ENDPTS
19 Apr 2023
Share Share
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine

U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
PRESS RELEASE
17 Apr 2023
Share Share
AbbVie`s Qulipta Outperforms Pfizer`s Nurtec ODT in Preventive Migraine Space

AbbVie`s Qulipta Outperforms Pfizer`s Nurtec ODT in Preventive Migraine Space
PR NEWSWIRE
16 Mar 2023
Share Share
AbbVie Submits MAA to EMA for Atogepant for Preventive Treatment of Migraine

AbbVie Submits MAA to EMA for Atogepant for Preventive Treatment of Migraine
PRNEWSWIRE
18 Jul 2022
Share Share
AbbVie Submits sNDA to U.S. FDA for Atogepant to Support Label Expansion

AbbVie Submits sNDA to U.S. FDA for Atogepant to Support Label Expansion
PRESS RELEASE
22 Jun 2022
Share Share
AbbVie Prepares to Seek Supplemental Approval for Migraine Treatment

AbbVie Prepares to Seek Supplemental Approval for Migraine Treatment
Alex Keown BIOSPACE
11 Mar 2022
Share Share